Hemato-oncology
Supportive MSC therapy for hematological and oncological conditions
Hemato-oncology represents one of the fastest-evolving areas of cell therapy. Mesenchymal stem cells play a crucial role in supportive therapy following bone marrow transplantation, helping to reduce graft-versus-host disease (GvHD) and accelerate hematopoietic recovery.
MSC cells have a unique ability to modulate the immune system, making them ideal for combination with existing oncological therapies. Clinical evidence shows that MSC therapy improves patient survival after allogeneic bone marrow transplantation and reduces the severity of acute GvHD.
GaiaCell is developing advanced MSC preparations optimized for hemato-oncological applications, including support for CAR-T therapies and tumor microenvironment modulation. All our therapies comply with strict EU ATMP regulatory standards.
Clinical Evidence & Statistics
Reduction in GvHD severity
Faster hematopoietic recovery
Clinical trials ongoing
Want to Learn More?
Fill out our questionnaire or contact us for a free consultation about MSC therapy options for your condition.
